MedTrace Logo

The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI

NCT02658838 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2016-01-20

No results posted yet for this study

Summary

The purpose of this study is to determine ticagrelor combining with low molecular weight heparin is effective and safe during PCI or not.

Conditions

  • LOVASTATIN/TICAGRELOR [VA Drug Interaction]

Interventions

DRUG

Ticagrelor

Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

DRUG

full amount low molecular weight heparin

Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

DRUG

half amount low molecular weight heparin

Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

DRUG

No low molecular weight heparin

Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • jinghua Liu · Beijing Anzhen hosipital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-08-31
Completion
2017-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02658838 on ClinicalTrials.gov